Roth Capital Maintains Buy On Lion Biotechnologies Shares, $20 PT
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Lion Biotechnologies (OTC:LBIO) with a price target of $20.00.
Pantginis observed, “Major background activities are underway at Lion and we expect significant and positive outcomes. Our confidence in our underlying investment case has been bolstered. We expect Lion to deliver a strong “package deal” with regard to owned IP and exclusive licenses based on its preliminary goal of bringing melanoma forward with the current technology and also multiple tumor indications with exclusive next generation technologies.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -11.9% and a 33.1% success rate. Pantginis has a -7.1% average return when recommending LBIO, and is ranked #3327 out of 3337 analysts.